肿瘤学人工智慧市场－全球产业规模、份额、趋势、机会和预测，按成分、癌症类型、治疗类型、地区和竞争细分，2020-2030 年

2024 年全球肿瘤人工智慧市场价值为 7.0108 亿美元，预计到 2030 年将以 9.43% 的复合年增长率成长。由于全球癌症负担加重以及对更准确、更有效的诊断和治疗方案的需求不断增长，市场正获得强劲发展势头。人工智慧透过实现早期检测、影像分析、病理解释和个人化治疗计划，在肿瘤学中发挥变革性的作用。机器学习演算法、深度学习以及与 MRI 和 CT 扫描等成像技术的整合等创新正在提高诊断的精确度。监管机构的批准，例如 FDA 批准的人工智慧癌症检测设备，以及支援精准肿瘤学的 Tempus+ 等平台，正在加速其应用。此外，医疗机构、学术机构和人工智慧公司之间的合作也促进了技术进步。人工智慧能够分析大量资料集并支援即时临床决策，这使它成为从诊断到治疗后监测的癌症治疗的重要工具。

关键市场驱动因素

提高诊断准确性

主要市场挑战

互通性和数据集成

主要市场趋势

人工智慧驱动的放射组学

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球肿瘤学人工智慧市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按组件（软体解决方案、硬体、服务）
  • 依癌症类型（乳癌、肺癌、摄护腺癌、大肠癌、脑瘤、其他）
  • 依治疗类型（化疗、放疗、免疫疗法、其他）
  • 按地区（北美、欧洲、亚太、南美、中东和非洲）
  • 按公司分类（2024）
• 市场地图

第六章：北美肿瘤人工智慧市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲肿瘤人工智慧市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区肿瘤人工智慧市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美洲肿瘤学人工智慧市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东和非洲肿瘤人工智慧市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 併购
• 产品发布

第 13 章：全球肿瘤学人工智慧市场：SWOT 分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章：竞争格局

• Azra AI.
• IBM Corp.
• Siemens Healthcare GmbH.
• Intel Corporation.
• GE HealthCare.
• NVIDIA Corporation.
• Digital Diagnostics Inc.
• ConcertAI.
• Median Technologies.
• PathAI.

第 16 章：策略建议

第17章调查会社について・免责事项

The Global AI in Oncology Market was valued at USD 701.08 Million in 2024 and is projected to grow at a CAGR of 9.43% through 2030. The market is gaining strong momentum due to the increasing global burden of cancer and the growing demand for more accurate and efficient diagnostic and treatment options. Artificial intelligence is playing a transformative role in oncology by enabling early detection, image analysis, pathology interpretation, and personalized treatment planning. Innovations such as machine learning algorithms, deep learning, and integration with imaging technologies like MRI and CT scans are enhancing diagnostic precision. Regulatory approvals, such as the FDA's clearance of AI-powered cancer detection devices, and platforms like Tempus+ that support precision oncology, are accelerating adoption. Additionally, collaborations between healthcare providers, academic institutions, and AI companies are contributing to technological advancements. AI's ability to analyze vast datasets and support real-time clinical decisions is positioning it as a vital tool in cancer care, from diagnosis to post-treatment monitoring.

Key Market Drivers

Improving Diagnostic Accuracy

AI's ability to interpret medical images with high precision is driving its adoption in oncology. By identifying complex patterns in radiological scans such as MRIs and CTs, AI supports early cancer detection and improves diagnostic outcomes. A 2022 NCBI study emphasized how AI significantly enhances the detection of mammographic abnormalities, helping healthcare professionals diagnose cancer at earlier, more treatable stages. Unlike human interpretation, which can vary due to fatigue or experience, AI delivers consistent, objective analysis. This reduces the risk of misdiagnosis and increases confidence among clinicians. Moreover, AI-driven systems support cancer screening programs by efficiently analyzing high volumes of imaging and pathology data, improving throughput and reducing diagnostic delays across healthcare systems.

Key Market Challenges

Interoperability and Data Integration

Data fragmentation across healthcare systems is a major barrier to the seamless deployment of AI in oncology. Variations in electronic health record (EHR) platforms, imaging technologies, and data formats hinder the ability to integrate and standardize patient data. For AI systems to function effectively, comprehensive access to medical history, imaging records, and genomic profiles is critical. However, lack of compatibility and uniform standards often leads to inconsistent or incomplete data inputs. This affects the reliability of AI-driven recommendations and creates trust issues among healthcare providers. Data integration challenges also slow the training and validation of AI models, ultimately impacting clinical adoption and scalability.

Key Market Trends

AI-Driven Radiomics

AI-powered radiomics is emerging as a key trend, enabling the extraction of detailed imaging features that reflect tumor behavior and biological properties. By analyzing micro-patterns and textures in medical scans, AI systems can detect cancer early, even before clinical symptoms arise. Radiomics not only improves diagnosis but also plays a pivotal role in treatment personalization. AI can link image-based features with molecular and genetic data, guiding precision therapies. Additionally, radiomics tools assist in real-time treatment monitoring by tracking how tumors respond to specific interventions. These systems enhance decision-making and reduce variability in radiological assessments. As AI radiomics becomes more integrated into oncology workflows, it is redefining standards for cancer screening, diagnosis, and outcome prediction.

Key Market Players

• Azra AI
• IBM
• Siemens Healthcare GmbH
• Intel Corporation
• GE HealthCare
• NVIDIA Corporation
• Digital Diagnostics Inc.
• ConcertAI
• Median Technologies
• PathAI

Report Scope:

In this report, the Global AI in Oncology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

AI in Oncology Market, By Component:

• Software Solutions
• Hardware
• Services

AI in Oncology Market, By Cancer Type:

• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Colorectal Cancer
• Brain Tumor
• Others

AI in Oncology Market, By Treatment Type:

• Chemotherapy
• Radiotherapy
• Immunotherapy
• Others

AI in Oncology Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global AI in Oncology Market.

Available Customizations:

Global AI in Oncology market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global AI in Oncology Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Component (Software Solutions, Hardware, Services)
  • 5.2.2. By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)
  • 5.2.3. By Treatment Type (Chemotherapy, Radiotherapy, Immunotherapy, Others)
  • 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America AI in Oncology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Component (Software Solutions, Hardware, Services)
  • 6.2.2. By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)
  • 6.2.3. By Treatment Type (Chemotherapy, Radiotherapy, Immunotherapy, Others)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States AI In Oncology Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Component
      • 6.3.1.2.2. By Cancer Type
      • 6.3.1.2.3. By Treatment Type
  • 6.3.2. Canada AI In Oncology Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Component
      • 6.3.2.2.2. By Cancer Type
      • 6.3.2.2.3. By Treatment Type
  • 6.3.3. Mexico AI In Oncology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Component
      • 6.3.3.2.2. By Cancer Type
      • 6.3.3.2.3. By Treatment Type

7. Europe AI In Oncology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Component (Software Solutions, Hardware, Services)
  • 7.2.2. By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)
  • 7.2.3. By Treatment Type (Chemotherapy, Radiotherapy, Immunotherapy, Others)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France AI In Oncology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Component
      • 7.3.1.2.2. By Cancer Type
      • 7.3.1.2.3. By Treatment Type
  • 7.3.2. Germany AI In Oncology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Component
      • 7.3.2.2.2. By Cancer Type
      • 7.3.2.2.3. By Treatment Type
  • 7.3.3. United Kingdom AI In Oncology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Component
      • 7.3.3.2.2. By Cancer Type
      • 7.3.3.2.3. By Treatment Type
  • 7.3.4. Italy AI In Oncology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Component
      • 7.3.4.2.2. By Cancer Type
      • 7.3.4.2.3. By Treatment Type
  • 7.3.5. Spain AI In Oncology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Component
      • 7.3.5.2.2. By Cancer Type
      • 7.3.5.2.3. By Treatment Type

8. Asia-Pacific AI In Oncology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Component (Software Solutions, Hardware, Services)
  • 8.2.2. By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)
  • 8.2.3. By Treatment Type (Chemotherapy, Radiotherapy, Immunotherapy, Others)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China AI In Oncology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Component
      • 8.3.1.2.2. By Cancer Type
      • 8.3.1.2.3. By Treatment Type
  • 8.3.2. India AI In Oncology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Component
      • 8.3.2.2.2. By Cancer Type
      • 8.3.2.2.3. By Treatment Type
  • 8.3.3. Japan AI In Oncology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Component
      • 8.3.3.2.2. By Cancer Type
      • 8.3.3.2.3. By Treatment Type
  • 8.3.4. South Korea AI In Oncology Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Component
      • 8.3.4.2.2. By Cancer Type
      • 8.3.4.2.3. By Treatment Type
  • 8.3.5. Australia AI In Oncology Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Component
      • 8.3.5.2.2. By Cancer Type
      • 8.3.5.2.3. By Treatment Type

9. South America AI In Oncology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Component (Software Solutions, Hardware, Services)
  • 9.2.2. By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)
  • 9.2.3. By Treatment Type (Chemotherapy, Radiotherapy, Immunotherapy, Others)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil AI In Oncology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Component
      • 9.3.1.2.2. By Cancer Type
      • 9.3.1.2.3. By Treatment Type
  • 9.3.2. Argentina AI In Oncology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Component
      • 9.3.2.2.2. By Cancer Type
      • 9.3.2.2.3. By Treatment Type
  • 9.3.3. Colombia AI In Oncology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Component
      • 9.3.3.2.2. By Cancer Type
      • 9.3.3.2.3. By Treatment Type

10. Middle East and Africa AI In Oncology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Component (Software Solutions, Hardware, Services)
  • 10.2.2. By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)
  • 10.2.3. By Treatment Type (Chemotherapy, Radiotherapy, Immunotherapy, Others)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa AI In Oncology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Component
      • 10.3.1.2.2. By Cancer Type
      • 10.3.1.2.3. By Treatment Type
  • 10.3.2. Saudi Arabia AI In Oncology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Component
      • 10.3.2.2.2. By Cancer Type
      • 10.3.2.2.3. By Treatment Type
  • 10.3.3. UAE AI In Oncology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Component
      • 10.3.3.2.2. By Cancer Type
      • 10.3.3.2.3. By Treatment Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global AI In Oncology Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Azra AI.
  • 15.1.1. Business Overview
  • 15.1.2. Product Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Key Personnel
  • 15.1.6. SWOT Analysis
• 15.2. IBM Corp.
• 15.3. Siemens Healthcare GmbH.
• 15.4. Intel Corporation.
• 15.5. GE HealthCare.
• 15.6. NVIDIA Corporation.
• 15.7. Digital Diagnostics Inc.
• 15.8. ConcertAI.
• 15.9. Median Technologies.
• 15.10. PathAI.

16. Strategic Recommendations

17. About Us & Disclaimer